The consensus report highlights shared guideline recommendations from the ADA 2022 Standards of Medical Care in Diabetes and KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.
A multicenter randomized controlled trial was conducted to assess the impact of a web-based, diabetes evaluation portal and team-based care on outcomes in patients with diabetic kidney disease.